Ingredient in MS, Psoriasis Drugs Linked to Two Deadly Brain Infections. WEDNESDAY, April 8, 2015 An active ingredient in some psoriasis and multiple sclerosis medications has been linked to two cases of a rare and sometimes lethal brain infection. Progressive multifocal leukoencephalopathy (PML) is a rare and usually fatal viral disease characterized by progressive damage (-pathy) or inflammation of the white matter (leuko-) of the brain (-encephalo-) at multiple locations (multifocal). PML is similar to another demyelinating disease, multiple sclerosis, but progresses much more quickly. The virus can then be carried into the brain, where it infects the white matter of the brain and attacks the cells responsible for making myelin, the protective coating that covers and protects nerve cells. PML can be disabling, even fatal. Further compounding the problem, several medications used to treat the symptoms of MS can compromise the immune system.
It’s an opportunistic viral infection of the central nervous system (CNS) that typically occurs in people with an immune deficiency due to immunosuppressive medications. There have been several other drugs that have been linked to the deadly PML brain infections in recent years. The psoriasis drug Raptiva was recalled in April of 2009 due to PML infections, and the cancer drug Rituxan was recently connected to 57 cases of PML infection in a study published in the May 2009 issue of the medical journal Blood. Drugs & SupplementsGet information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Ingredient in MS Psoriasis Drugs Linked to Two Deadly Brain Infections. Multiple sclerosis, or MS, is a disease of the central nervous system. MS is an autoimmune disease (like rheumatoid arthritis, psoriasis, and type 1 diabetes). MS is rarely fatal, and many people with MS have a life expectancy that’s about as long as that of the general population.
PML is a rare but potentially fatal brain infection caused by the JC virus. Severe and fatal cardiac rhythm disturbances were observed during preapproval testing of Gilenya (fingolimod), primarily bradycardia and heart block occurring soon after initiating treatment. This is the sixth MS patient who has been diagnosed with PML since Tysabri was reintroduced on the market in July 2006. We will watch for any additional reports of the brain infection PML in patients using Tysabri from Biogen — which, as stated above, will be providing weekly reports at least until July 24, 2009 — or from other sources. (PML), a rare brain infection, in patients using the psoriasis drug Raptiva. Evaluate your current MS treatment and get some guidance to have a discussion with your neurologist.
Symptoms depend on where in the brain the virus hits and can include deficits in speech, vision, movement and thought processes. More recently, certain drugs — including Raptiva, the multiple sclerosis drug Tysabri and the rheumatoid arthritis drug Rituxan — have been linked with PML. Tecfidera joins Gilenya and Aubagio as the only MS treatments currently in pill form. Now back to Fumaderm, Tecfidera’s very effective German anti-psoriasis cousin. (click here), the opportunistic brain infection associated with Tysabri. The BG-12 material that I have read said that four psoriasis patients who took a similar drug developed rare but sometimes deadly conditions. Relapsing MS is a disease that we have treatments for, but they’re really on two ends of the spectrum, says Dr. You know no one is paying that much for a food additive or a psoriasis drug, but they will still increase the price dramatically now that they have found another use for it. Treatment options for moderate to severe psoriasis include topical and systemic medications, phototherapy, and excimer laser, Combination therapies are often more effective than one treatment alone. Pregnant and nursing mothers should never take methotrexate because it increases the risk for severe, even fatal, birth defects and miscarriage. The multiple sclerosis drug Tysabri (natalizumab) increases the risk of a fatal brain virus ten-fold. Progressive multifocal leukoencephalopathy (PML) is a rare disease that attacks the brain’s white matter but it becomes more common when the immune system is compromised, as can happen when people take immunosuppressive drugs, say researchers.